Albertan with rare blood cancer calls on Health Canada to approve life-saving drug

20 January 2025 - An Alberta woman living with a rare form of blood cancer is calling on Health Canada ...

Read more →

Takeda's Fruzaqla (fruquintinib) receives Health Canada market authorisation for metastatic colorectal cancer

20 January 2025 - Positive reimbursement recommendations by Canada's Drug Agency and Institut National d'excellence en Santé et Services Sociaux. ...

Read more →

Long wait for cancer drug approvals causing 'great anguish' among patients, doctors

18 January 2025 - Potentially life-saving treatments delayed by bureaucracy, doctors say. ...

Read more →

Rybrevant plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR mutated advanced lung cancer

16 January 2025 - Phase 3 MARIPOSA-2 study showed Rybrevant in combination with carboplatin and pemetrexed significantly improved progression-free survival compared ...

Read more →

CAR T cell therapy Breyanzi (lisocabtagene maraleucel) approved for second-line relapsed or refractory diffuse large B-cell lymphoma

13 January 2024 - In the pivotal Phase 3 TRANSFORM trial, Breyanzi demonstrated a significant improvement in event-free survival over ...

Read more →

Astellas receives Health Canada approval for Vyloy (zolbetuximab) in combination with chemotherapy for advanced gastric and gastro-oesophageal junction cancer

9 January 2024 - Canada's Drug Agency recently issued draft recommendation to reimburse Vyloy with conditions. ...

Read more →

Health Canada authorises Carvykti (ciltacabtagene autoleucel) for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy

21 November 2024 - Authorisation is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with ...

Read more →

Health Canada approves first and only oral targeted treatment for brain cancer

22 October 2024 - Pivotal Phase 3 study shows significant improvement in progression-free survival with a favourable safety profile. ...

Read more →

Health Canada approves label expansion for Telix’s Illuccix to include patient selection for PSMA targeted therapy

4 October 2024 - Telix Pharmaceuticals today announces that Health Canada has approved the use of Illuccix (kit for the ...

Read more →

Health Canada approves Keytruda as monotherapy for the treatment of adult and paediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumours that have progressed following prior treatment and who have no satisfactory alternative treatment options

12 September 2024  - Merck announced that Health Canada has granted approval of Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, as a monotherapy ...

Read more →

Padcev (enfortumab vedotin) in combination with pembrolizumab approved by Health Canada to treat advanced bladder cancer

22 August 2024 - Padcev plus pembrolizumab approved based on EV-302 trial. ...

Read more →

Health Canada approves Keytruda for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer with no prior systemic therapy for metastatic urothelial cancer, in combination with enfortumab vedotin

22 August 2024 - Approval is based on the Phase 3 KEYNOTE-A39 trial. ...

Read more →

Health Canada grants full approval to Jemperli for the treatment of patients with recurrent or advanced dMMR/MSI-H endometrial cancer

24 July 2024 - The conversion of this indication from Notice of Compliance to full approval is based on long term ...

Read more →

Health Canada authorizes Alecensaro (alectinib) as the first and only adjuvant treatment for people with ALK positive early stage lung cancer

16 July 2024 - Alecensaro reduced the risk of disease recurrence or death by 76% in people with ALK positive resected ...

Read more →

Health Canada approves Tagrisso with the addition of chemotherapy for patients with EGFR mutated advanced lung cancer

12 July 2024 - Approval based on FLAURA2 results, which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly ...

Read more →